Method of use of eritoran as a TLR4 antagonist for treatment of ebola and Marburg disease
US11185554B2 · kind B2 · utility
0Cited by
1References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 14, 2017 |
| Grant date | Nov 30, 2021 |
| Priority date | — |
| Expiry date | Sep 14, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to methods for treating ebola virus infections or Marburg virus infections comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.